Canada markets closed

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.2500+0.2000 (+9.76%)
At close: 04:00PM EDT
2.3900 +0.14 (+6.22%)
After hours: 05:12PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.0500
Open2.0700
Bid2.1000 x 900
Ask2.4000 x 1800
Day's Range2.0700 - 2.2600
52 Week Range1.4500 - 13.7700
Volume115,014
Avg. Volume161,404
Market Cap56.878M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.0050
Earnings DateAug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
  • GlobeNewswire

    Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights

    TERN-701 (allosteric BCR-ABL inhibitor) advances into Phase 1 trial for CML in ChinaIND-enabling activities for TERN-601 (GLP-1R agonist) remain on track; Phase 1 obesity trial initiation expected in 2023Initiated dosing of TERN-501 (THR-β agonist) Phase 2a DUET combo clinical trial for NASH; top-line data expected in second half of 2023Cash and equivalents of $140 million provides runway into 2025, supporting three expected clinical trial readouts across three product candidates and three indic

  • GlobeNewswire

    Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

    FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced the appointment of Radhika Tripuraneni, M.D., M.P.H. to the Company’s Board of Directors. Dr. Tripuraneni serves as the Chief Development Officer of Prothena Cor

  • Zacks

    All You Need to Know About Terns Pharmaceuticals, Inc. (TERN) Rating Upgrade to Buy

    Terns Pharmaceuticals, Inc. (TERN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.